Specific cyclooxygenase-2 inhibitor analgesics: Therapeutic advances;Analgésicos inibidores específicos da ciclooxigenase-2: Avanços terapêuticos

Revista Brasileira de Anestesiologia

Volumn 54, Issue 3, 2004, Pages 448-464

  Andrade Carvalho, Wilson ^a,b,c   Sales Carvalho, Rosemary Duarte ^d   Rios Santos, Fabrício ^e  

^a Farmacologia da UESC   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c HOSPITAL SÃO RAFAEL   (Brazil)

^d Farmacol da Fac de Farmacia UFBA

^e Farmacol do Depto de Saude FMUESC

Author keywords

Anti inflammatory: COX 2 inhibitors; Pain, Chronic: cancer

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FENOPROFEN; FURANONE DERIVATIVE; IBUPROFEN; INDOLEACETIC ACID; KETOPROFEN; KETOROLAC; LITHIUM; MEFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; RS 57067000; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL PAIN; ALLERGIC VASCULITIS; ALZHEIMER DISEASE; ANALGESIA; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DUODENUM ULCER; DYSPEPSIA; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; LITHIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NONHUMAN; PAIN; PATENT DUCTUS ARTERIOSUS; PATIENT MONITORING; PROSTAGLANDIN SYNTHESIS INHIBITION; PURPURA; REVIEW; SIDE EFFECT; STOMACH ULCER; SUDDEN DEATH; THROMBOSIS; TONGUE DISEASE; TRANSIENT ISCHEMIC ATTACK; ULCER PERFORATION; UNSTABLE ANGINA PECTORIS; URTICARIA;

EID: 2542448945     PISSN: 00347094     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-70942004000300017     Document Type: Review

References (81)

1. Dubois RN, Abramson SB, Crofford L et al - Cycloxygenase in biology and disease. FASEB J, 1998;12:1063-1073.
2. Vane JR - Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971;231:232-235.
3. DeWitt DL, Smith WL - Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci, 1988;85:1412-1416.
4. Kujubu DA, Fletcher BS, Varnum BC et al - TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ciclooxygenase homologue. J Biol Chem, 1991;266:12866-12872.
5. Xie W, Chipman JG, Robertson DL et al - Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci, 1991;88: 2692-2696.
6. Crofford LJ - COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol, 1997;24:15-19.
7. Vane JR, Bakhle YS, Botting RM - Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol, 1998;38:97-120.
8. Kulkarni SK, Jain NK, Singh A - Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol, 2000;22:291-298.
9. Fitzgerald GA, Patrono C - The coxibs, selective inhibitors of cyclooxigenase-2. N Engl J Med, 2001;345:433-442.
10. a Ed, São Paulo, Artes Médicas, 2000;265-280.
11. Chandrasekharan NV, Dai H, Roos KL et al - COX-3, a cyclooxygensase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci, 2002;99:13926-13931.
12. th Ed, New York, Garland Publishing/Churchill Livingstone, 2001.
13. Morrow JD, Roberts LJ - Lipid-Derived Autacoids. Eicosanoids and Platelet-Activating Factor, em: Hardman JG, Limbird LE, Gilman AG - Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2001;669-685.
14. a Ed, Rio de Janeiro, Guanabara Koogan, 2002;431-455.
15. Samuelsson B, Granstrom E, Green K et al - Prostaglandins. Ann Rev Biochem, 1975;44:669-694.
16. Samuelsson B - The leukotrienens: a new group of biologically active compounds including SRS-A. Trends Pharmacol Sci, 1980;1: 227-230.
17. Carvalho WA - Mecanismos de ação das drogas anti-inflamatórias não-esteróides. I. Ações farmacológicas das prostaglandinas e leucotrienos. F Med, 1990;100:37-44.
18. Carvalho WA - Mecanismos de ação de drogas antiinflamatórias não-esteróides. II. Ações analgésicas, antiinflamatórias e antipiréticas. F Med, 1990;100:111-122.
19. Raz A, Wyche A, Needleman P - Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci, 1989;86:1657-1661.
20. Fu JY, Masferrer JL, Seibert K et al - The induction and suppression of prostaglandin H2 synthase (cyclooxigenase) in human monocytes. J Biol Chem, 1990;265:16737-16740.
21. Mitchell JA, Akarasereenont P, Thiemermann C et al - Selectivity of nonsteroid anti-inflammatory drugs as inhibitors of constitutive and inducible ciclooxygenase. Proc Natl Acad Sci, 1993;90: 11693-11697.
22. Meade EA, Smith WL, Dewitt DL - Differential inhibition of spinal nociceptive processing. Pain, 1993;9-43.
23. Vane JR, Bottingg RM - New insights into the mode of action of anti-inflammatory drugs. Inflamm Res, 1995;1-10.
24. Jouzeau Y, Terlain B, Abid A et al - Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs, 1997;53:563-582.
25. Morisset S, Patry C, Lora, M et al - Regulation of cyclooxygense-2 expression in bovine chondrocytes in culture by interleukin 1α, tumor necrosis factor-α, glucocorticoids, and 17β-estradiol. J Rheumatol, 1998;25:1146-1153.
26. Hinz B, Brune K - Cyclooxygenase-2 10 years later. J. Pharmacol. Exp Ther, 2002;300:367-375.
27. Kurumbail RG, Stevens AM, Gierse JK et al - Structural basis for selective inhibition of cyclooxigenase-2 by anti-inflammatory agents. Nature, 1996;384:644-648.
28. Cryer B, Dubois A - The advent of higly selective inhibitors of cyclooxigenase. A review. Prostaglandins, 1998;56:341-361.
29. th International Conference on Prostaglandins and Related Compounds. Florence, Italy, 1994;6-10.
30. Devchand PR, Keller H, Peters JH et al - The PPARα-leukotriene B4 pathway to inflammatory control. Nature, 1996;384:39-43.
31. Hla T, Bishop-Bailey D, Liu CH et al - Cyclooxygenase-1 and -2 isoenzymes. Int J Bioch Cell Biol, 1999;31:551-557.
32. Coleman RA, Smith WL, Narumiya S - International Union of Pharmacology classification of prostanoid receptors and clinical potential distribution, and structure of the receptors and their subtypes. Pharmacol Rev, 1994;46:205-229.
33. Graziano MP, Gilman AG - Guanine nucleotide-binding regulatory protein: mediators of transmembrane signaling. Trends Pharmacol Sci, 1987;8:478-481.
34. Colville-Nash PR, Qureshi SS, Willis D et al - Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol, 1998;161:978-984.
35. Gilroy DW, Tomlinson A, Willoughby DA - Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res, 1998;47:79-85.
36. Gilroy DW, Colville-Nash PR, Willis D et al - Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med, 1999;5:698-701.
37. Jiang C, Ting AT, Seed B - PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998;391: 82-86.
38. Ricote M, Huang J, Fajas L et al - Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA, 1998;95:7614-7619.
39. Ricote M, Li AC, Willson TM et al - The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998;391:79-82.
40. Willoughby DA, Moore AR, Colville-Nash PR - COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 2000;355:646-648.
41. a Ed, São Paulo, Artes Médicas, 2000;281-296.
42. Ferreira SH, Vane JR - Mode of Action of Anti-Inflammatory Agents which are Prostaglandin Synthetase Inhibitory, em: Vane JR, Ferreira SH - Anti-Inflammatory Drugs. New York, Springer-Verlag, 1979;348-398.
43. Moncada S, Ferreira SH, Vane JR - Pain and Inflammatory Mediators, em: Vane JR, Ferreira SH - Hand Books of Experimental Inflammation. New York, Springer-Verlag, 1978;588-616.
44. Moncada S, Vane JR - Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev, 1978;30:293-331.
45. Piper P, Vane J - The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci, 1971;180:383-385.
46. Fischer JW, Gross DM - Effects of Prostaglandins on Erythropoiesis, em: Silver M, Smith BJ, Kocsis JJ - Prostaglandins in Haematology. New York, Spectrum Publications Inc, 1977; 159-185.
47. Cohn SM, Schloemann S, Tessner T et al - Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest, 1997;99: 1367-1379.
48. Yamagata K, Andreasson KI, Kaufmann WE et al - Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and gluccorticoids. Neuron, 1993;11:371-386.
49. Breder C, Saper CB - Expression of inducible cycloxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolyssaccharide. Brain Res, 1996;713:64-69.
50. Kaufmann WE, Worley PF, Pegg J - COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci, 1996;93:2317-2321.
51. 2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem, 1997;68:704-709.
52. Panara MR, Renda G, Sciulli MG et al - Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther, 1999;290: 276-280.
53. Picot D, Loll PJ, Garavito RM - The X-ray crystal structure of the membrane protein prostaglandin H2 synthase 1. Nature, 1994;367: 243-249.
54. Hull M, Lieb K, Fiebich BL - Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin Investig Drugs, 2000;9:671-683.
55. Hawkeu CJ - COX-2 Inhibitors. Nature, 1999;353:307-314.
56. Williams CS, Smalley W, DuBois RN - Aspirin use and potential mechanisms for coloretal cancer prevention. J Clin Invest, 1997;100:1325-1329.
57. Baron JA, Cole BF, Sandler RS et al - A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med, 2003;348:891-899.
58. Sandler RS, Halabi S, Baron JA et al - A randomized trial of aspirin to prevent corectal adenomas in patients with previous colorectal cancer. N Engl J Med, 2003;348:883-890.
59. Zhang Z, DuBois RN - Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene, 2001;20:4450-4456.
60. Steinbach G, Lynch PM, Phillips RKS et al - The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med, 2000;342:1946-1952.
61. Kundu N, Fulton AM - Selective cyclooxygenase COX-1 or COX-2 inhibits control metastatic disease in a murine model of breast cancer. Cancer Res, 2002;62:2343-2346.
62. Kaur BS, Khamnehei N, Iravani M et al - Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology, 2002;123:60-67.
63. Singh-Ranger G, Mokbel K - Current concepts in cyclooxygenase inhibition in breast cancer. J Clin Pharm Ther, 2002;27:321-327.
64. Wu GD - A nuclear receptor to prevent colon cancer. N Engl J Med, 2000;342:651-653.
65. He TC, Chan TA, Kinzler KW - PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999;99:335-345.
66. Barnes CJ, Lee M - Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli min mouse model with aspirin. Gastroenterology, 1998;114:873-877.
67. Lynch HT, Chapelle A - Hereditary colorectal cancer. N Engl J Med, 2003;348:919-932.
68. 2 in human breast cancer and metastasis. Int J Cancer, 2003;103:84-90.
69. Eibl G, Reber HA, Wente MN et al - The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas, 2003;26:33-41.
70. Subongkot S, Frame D, Leslie W et al - Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy, 2003;23:9-28.
71. Mukherjee D, Nissen SE, Topol EJ - Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001;286: 954-959.
72. Mukherjee D, Nissen SE, Topol EJ - COX-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Cleve Clin J Med, 2001;68:963-964.
73. Whelton A - Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am J Med, 2001;110:(Suppl)33S-42S.
74. Grob M, Scheidegger P, Wuthrich B - Allergic skin reaction to celecoxib. Dermatology, 2000;201:383.
75. Knowles S, Shapiro L, Shear NH - Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Saf, 2001;24:239-247.
76. Ahmad SR, Kortepeter C, Brinker A et al - Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf, 2002;25:537-544.
77. Ernst EJ, Egge JA - Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy, 2002;22:637-640.
78. Rocha JL, Fernandez-Alonso J - Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet, 2001;357:1946-1947.
79. Schneider F, Meziani F, Chartier C et al - Fatal allergic vasculitis associated with celecoxib. Lancet, 2002;359:852-853.
80. FitzGerald GA - Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet, 2003;361:542-544.
81. MacDonald TM, Wei L - Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003;361:573-574.